article thumbnail

Cosmetics safety misconceptions with Mo Kanadil PharmD AKA @Moskinlab

The Eco Well Podcasts

This episode features safety assessor Mo Kanadil PharmD, otherwise known as @Moskinlab , in a conversation about safety misconceptions. What are common safety misconceptions amongst consumers, where is the misinformation coming from, what are the challenges in addressing it, and more. Interested in supporting the podcast?

Safety 75
article thumbnail

Cosmetic Dermatology in the Digital Age: How to Harness Technology and Uphold Safety and Ethics

The Dermatology Digest

Cosmetic dermatologists must learn to harness technology while upholding the core values of safety, ethics, and patient satisfaction, writes Neelam Vashi, MD, an Associate Professor of Dermatology at Boston University Chobanian & Avedisian School of Medicine in Boston, MA, in the Journal of Clinical Medicine.

Ethics 74
article thumbnail

Important Updates on the Efficacy and Safety of JAK Inhibitors in Dermatology

The Dermatology Digest

Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, IL, reviews the latest efficacy and safety data on oral and topical Janus kinase (JAK) inhibitors used in dermatology. He spoke on this topic at the 2024 Revolutionizing Atopic Dermatitis (RAD) Conference.

Safety 74
article thumbnail

Florida's New BBL Safety Law Praised by Cosmetic Surgeons

MedEsthetics

Florida's new law mandating the use of ultrasound guidance during gluteal fat grafting procedures has been praised by the AACS and ABCS for implementing improved patient safety measures without limiting surgeons' right to practice.

Safety 147
article thumbnail

Sunscreen safety and the FDA situation: Huberman’s skincare podcast response (Part 2)

Lab Muffin Beauty Science

The most controversial topic in Dr Andrew Huberman’s skincare episode is probably sunscreen safety, which is hugely misunderstood even by scientists and medical doctors.

Safety 52
article thumbnail

Icotrokinra Shows Efficacy and Safety in Adolescents With Moderate to Severe PsO

The Dermatology Digest

” Icotrokinra demonstrated a favorable safety profile. At Week 16, 50% of adolescents treated with icotrokinra experienced 1 adverse event (AE), compared to 73% of adolescents receiving placebo, with no new safety signals identified. and Janssen Biotech, Inc., a Johnson & Johnson company. . and Janssen Biotech, Inc.,

Safety 36
article thumbnail

Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis

Dermatology Times

Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis. Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years. Brodalumabs 5-year pharmacovigilance (Lebwohl, 2024) and 120-week data (Puig, 2020) support its long-term use.

Safety 36